CVM | tickerfilter.com

Fundamental analysis

31%

Profitability 25%

Dept financing 25%

Liquidity 10%

Performance 45%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

2.87%

1 Month

-24.95%

3 Months

-37.16%

6 Months

-61.93%

1 Year

1,036.43%

2 Year

72.81%

Key data

Stock price

$3.94

P/E Ratio

0.00

DAY RANGE

$3.67 - $4.12

EPS

-$1.21

52 WEEK RANGE

$0.18 - $13.48

52 WEEK CHANGE

$1,138.60

MARKET CAP

44.230 M

YIELD

N/A

SHARES OUTSTANDING

8.458 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

$60,657

AVERAGE 30 VOLUME

$48,707

Company detail

CEO: Geert R. Kersten
Region: US
Website: cel-sci.com
Employees: 43
IPO year: 1991

Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for head and neck cancer. Its Ligand Epitope Antigen Presentation System stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.

CVM - CEL SCI CORP